Scholarlink

<p>The current study establishes the mechanism on how dietary flavonoid, catechin fractions of <i>Osbeckia parvifolia</i> Arn. could be used as a therapeutic treatment for ovarian cancer, using a combination of network pharmacology, molecular validation and nano-formulations. From network modelling analysis, 420 protein targets linked to ovarian cancer, including five that act as major regulatory hubs – AKT1, STAT3, IL6, ESR1 and CASP3 were found. Catechin had the strongest binding affinity to all of these five hub proteins, especially for ESR1 (-11.089&#xa0;kcal/mol) and AKT1 (-9.221&#xa0;kcal/mol). In molecular dynamics simulation studies over 100 ns, catechin bonded strongly with its target proteins. HPLC guided fractionation (RT: 3.887&#xa0;min) LC-MS/MS (RT:6.51&#xa0;min), HPTLC (Rf: 0.973) were performed, which resulted in the confirmation of the presence of both catechin and epicatechin and verified the biosynthetic pathway of both through the measurement of the expression of their respective biosynthetic genes LAR (0.3637 folds) and ANR (0.2746 folds) in <i>O. parvifolia</i>. The evaluation of the six different nano-formulations of phytoniosomes led to F5 being the most stable with uniform spherical architecture, having an optimal particle size (229.2&#xa0;nm), a high positive zeta potential (+ 42.7mV), and having the highest cytotoxicity (93.17%) in SKOV3 cells, the mechanism of action being through apoptosis induction and cell-cycle arrest. Hence, this study supports the hypothesis that catechin extracted from <i>O. parvifolia</i> can serve as an effective therapeutic candidate for the targeted treatment of ovarian cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Catechin–Folate nano-niosomes from Osbeckia parvifolia Arn. induce apoptotic cell death in Ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Benedict Mathews Paul,
  • Gowtham Kannan,
  • Yamuna Annadurai,
  • Parimelazhagan Thangaraj

摘要

The current study establishes the mechanism on how dietary flavonoid, catechin fractions of Osbeckia parvifolia Arn. could be used as a therapeutic treatment for ovarian cancer, using a combination of network pharmacology, molecular validation and nano-formulations. From network modelling analysis, 420 protein targets linked to ovarian cancer, including five that act as major regulatory hubs – AKT1, STAT3, IL6, ESR1 and CASP3 were found. Catechin had the strongest binding affinity to all of these five hub proteins, especially for ESR1 (-11.089 kcal/mol) and AKT1 (-9.221 kcal/mol). In molecular dynamics simulation studies over 100 ns, catechin bonded strongly with its target proteins. HPLC guided fractionation (RT: 3.887 min) LC-MS/MS (RT:6.51 min), HPTLC (Rf: 0.973) were performed, which resulted in the confirmation of the presence of both catechin and epicatechin and verified the biosynthetic pathway of both through the measurement of the expression of their respective biosynthetic genes LAR (0.3637 folds) and ANR (0.2746 folds) in O. parvifolia. The evaluation of the six different nano-formulations of phytoniosomes led to F5 being the most stable with uniform spherical architecture, having an optimal particle size (229.2 nm), a high positive zeta potential (+ 42.7mV), and having the highest cytotoxicity (93.17%) in SKOV3 cells, the mechanism of action being through apoptosis induction and cell-cycle arrest. Hence, this study supports the hypothesis that catechin extracted from O. parvifolia can serve as an effective therapeutic candidate for the targeted treatment of ovarian cancer.